Vistagen completes PALISADE-3 Phase 3 trial; topline results due by year end

Vistagen Therapeutics, Inc.

Last patient completed randomized, double-blind, placebo-controlled portion of PALISADE-3 for fasedienol in social anxiety disorder; open-label extension ongoing.
Topline results for PALISADE-3 expected in Q4 2025; PALISADE-4 topline anticipated in H1 2026.
PALISADE-3 uses same design as positive PALISADE-2 trial (SUDS primary endpoint); FDA Fast Track designation in place.
Successful PALISADE-3 or -4 could support NDA submission for first acute treatment for social anxiety disorder (over 30M patients).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.